Investment Rating - The report maintains a "Buy" rating for the company with a target price of 111.83 CNY [4][2] Core Insights - The company demonstrated strong operational resilience with a revenue of 191 million CNY in H1 2024, reflecting a year-on-year growth of 13.7%. All three business segments reported revenue growth, with specific increases of 18.8% in valve replacement and repair, 11.0% in congenital heart disease interventions, and 10.3% in soft tissue repair. The core product, the bovine pericardial valve, saw a sales increase of 20.6% [1][2] - Despite a challenging market environment due to macroeconomic conditions and pressure from medical insurance payments, the company maintained a robust performance in surgical volumes, contributing positively to revenue. However, the net profit attributable to the parent company decreased by 20.4% year-on-year to 35 million CNY, primarily due to high R&D investments and share-based payments. The company continues to expect a revenue growth rate of 30-40% for the full year [1][2] - The company is solidifying its R&D efforts, with R&D expenses reaching approximately 75.22 million CNY in H1 2024, a significant increase of 110.8% year-on-year, accounting for 39.5% of revenue. The company is focused on basic research and the development of innovative products, with several products currently undergoing regulatory review [1][2] Financial Summary - The company reported a revenue of 295 million CNY in 2022, which increased to 371 million CNY in 2023, and is projected to reach 497 million CNY in 2024, representing a year-on-year growth of 34.0%. The net profit attributable to the parent company is expected to grow from 95 million CNY in 2022 to 161 million CNY in 2024 [3][8] - The gross margin is projected to improve from 89.4% in 2022 to 91.8% in 2024, while the net profit margin is expected to stabilize around 32.4% in 2024 [3][8] - The company has achieved a return on equity (ROE) of 9.1% in 2022, which is expected to rise to 13.1% by 2024, indicating improved profitability and efficiency [3][8]

证券代码：688198 证券简称：佰仁医疗 公告编号：2024-036 北京佰仁医疗科技股份有限公司 关于自愿披露创新产品"经导管主动脉瓣系统"获批注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，经国家药品监督管理局审查，北京佰仁医疗科技股份有限公司（以下简称 "公司"）具有自主知识产权的全球首个结构和工艺实现与外科生物瓣相同启闭模式的 球囊扩张式经导管主动脉瓣产品（国械注准20243131529）获准注册。依据已向国家药 品监督管理局提交的注册申请资料，对比以往国内已经注册上市的同类产品，该产品 具有颠覆性的技术创新。 对于人工生物瓣（包括外科生物瓣和经导管介入生物瓣），瓣膜的耐久性和抗钙 化性能是业界最为关注、研究最多的两个关键性能。目前外科牛心包生物瓣有大组长 期临床应用数据10-15年使用寿命，被公认为是生物瓣耐久性的金标准。除瓣叶组织抗 钙化改性技术外，其瓣叶交界固定在非管状单丝的弹性支架上使瓣叶启闭的应力最小 是获得耐久性的关键。公司这款经导管主动脉瓣，通过其专利技术-"瓣叶交界与网管 支架连 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][3] Core Views - The company achieved stable revenue growth in H1 2024, with a revenue of RMB 191 million, representing a year-on-year increase of 13.74% [2] - Significant increase in R&D expenses, reaching RMB 75.22 million in H1 2024, a 110.75% increase year-on-year, accounting for 39.45% of revenue [2] - The company’s three main business segments exceeded sales targets, with notable growth in valve replacement and repair business (up 18.79%), congenital heart disease intervention (up 10.98%), and soft tissue repair (up 10.29%) [2] - Core product sales, particularly for surgical biological valves, increased by 20.57%, maintaining a leading market share among domestic brands [2] - Accelerated R&D progress is expected to drive future revenue growth, with several key products nearing registration and clinical trials showing promising results [2] Financial Summary - Revenue projections for 2024-2026 are RMB 492 million, RMB 644 million, and RMB 855 million, with growth rates of 32.7%, 30.9%, and 32.7% respectively [3][4] - Net profit forecasts for the same period are RMB 164 million, RMB 229 million, and RMB 322 million, with growth rates of 42.6%, 39.5%, and 40.7% respectively [3][4] - The latest diluted EPS estimates are RMB 1.20, RMB 1.67, and RMB 2.35 for 2024, 2025, and 2026 respectively [3][4] - The company’s P/E ratios are projected to be 78.6, 56.4, and 40.1 for the years 2024, 2025, and 2026 respectively [3][4] Market Position - The company is positioned to leverage its brand advantages and expand into untapped markets while solidifying its competitive edge in core markets [2] - The report highlights the company's focus on optimizing product layout and expediting the R&D and registration processes for its key products [2]

北京佰仁医疗科技股份有限公司 章 程 2024 年 8 月 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 10 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 16 | | 第五节 | 股东大会的召开 18 | | 第六节 | 股东大会的表决和决议 21 | | 第五章 | 董事会 25 | | 第一节 | 董事 25 | | 第二节 | 董事会 28 | | 第六章 | 总经理及其他高级管理人员 35 | | 第七章 | 监事会 37 | | 第一节 | 监事 37 | | 第二节 | 监事会 38 | | 第八章 | 财务会计制度、利润分配和审计 40 | | 第一节 | 财务会计制度 40 | | 第二节 | 内部审计 44 | | 第三节 | 会计师事务所的聘任 44 | | ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2024-034 北京佰仁医疗科技股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第二次临时股东大会 召开日期时间：2024 年 9 月 18 日 14 点 00 分 召开地点：北京市昌平区科技园东区华昌路 2 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 18 日 至 2024 年 9 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 股东大会召开日期：2024年9月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2024-031 截至 2019 年 12 月 31 日，公司募集资金累计投入募投项目 13,002.43 万元，尚未 使用的金额为 38,269.13 万元（其中募集资金 37,594.61 万元，专户存储累计利息扣除 手续费 15.12 万元，自筹资金预先支付及未支付的发行费金额 659.40 万元）。 （三）2020 年度使用金额及年末余额 北京佰仁医疗科技股份有限公司 2024年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意北京佰仁医疗科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2019〕2225 号）同意注册，北京佰仁医疗科技股 份有限公司（以下简称"公司"）向社会公开发行人民币普通股 2,400 万股，每股面值 人民币 1 元，每股发行价为人民币 23.68 元，应募集资金人民币 56,832.00 万元，扣 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2024-033 北京佰仁医疗科技股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京佰仁医疗科技股份有限公司（以下简称"佰仁医疗"或"公司"）于 2024 年 8 月 21 日召开第三届董事会第五次会议、第三届监事会第四次会议，审议通过了《关于公司部 分募集资金投资项目延期的议案》，综合考虑当前募集资金投资项目（以下简称"募投 项目"）的实施进度等因素，同意公司将募投项目"昌平新城东区佰仁医疗二期建设项目" 的预定可使用状态日期延长至 2024 年 10 月。保荐机构国信证券股份有限公司（以下简 称"国信证券"）对本事项出具了明确的核查意见。本事项无需提交公司股东大会审议。 现将相关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意北京佰仁医疗科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2019〕2225号）同意注册， 公司向社会公开发行人民币普通股24, ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2024, representing a 20% increase compared to the same period last year[1]. - The company reported a revenue of RMB 1.2 billion for the first half of 2024, representing a year-over-year growth of 15%[12]. - The company anticipates a revenue guidance of RMB 2.5 billion for the full year 2024, reflecting a growth rate of 20%[12]. - The company achieved operating revenue of CNY 190,683,312.95 for the first half of 2024, representing a year-on-year increase of 13.74%[16]. - The company maintains its full-year revenue growth forecast of 30-40% compared to the previous year[16]. - The company reported a total revenue of 51,519 million RMB for the first half of 2024, with a net profit of 7,706.65 million RMB, representing a significant increase compared to the previous year[63]. - The company achieved a year-on-year revenue growth of 13.74%, laying a solid foundation for the annual target achievement[71]. - The company reported a net profit attributable to shareholders decreased by 20.42% to CNY 35,190,693.59 compared to the same period last year[16]. User Engagement and Market Expansion - User data indicates a growth in active users by 15%, reaching 1.2 million users as of June 2024[1]. - The number of patients treated with the company's products increased by 20% compared to the same period last year, reaching 150,000 patients[12]. - Market expansion efforts have led to entry into three new provinces, increasing the company's geographical footprint by 30%[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2025[12]. - The company is focusing on enhancing its digital health solutions, aiming for a 30% increase in user engagement by mid-2025[12]. Research and Development - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[1]. - The R&D expenditure for new product development was RMB 200 million, accounting for 16.7% of total revenue[12]. - R&D expenses reached CNY 7,521,890, accounting for 39.45% of operating revenue, an increase of 16.94 percentage points year-on-year[16]. - The company has established six new research centers to enhance R&D efficiency, focusing on various fields including biomechanics and AI[53]. - The company is actively pursuing multiple R&D projects, including the ViV and TAVR systems, with a total expected investment of ¥10 million, and has already invested ¥10.76 million to date[59]. Product Development and Innovation - New product launches in the first half of 2024 included two innovative medical devices, contributing to a 10% increase in market share[1]. - The company is set to launch a new minimally invasive heart valve replacement product in Q4 2024, expected to generate an additional RMB 300 million in revenue[12]. - The company has successfully completed the acquisition of a local competitor, which is expected to contribute an additional RMB 500 million in annual revenue[12]. - The company is developing a range of innovative products, including a minimally invasive heart valve repair system and various biological patches, with several products expected to complete clinical trials and receive regulatory approval in 2024[34]. - The company has launched a new expandable bovine pericardial valve and is developing a transcatheter valve-in-valve product, which has been submitted for registration review[21]. Financial Management and Investments - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for this purpose[1]. - The company has received approval for 20 Class III medical device products, including 10 first-of-their-kind domestic products in China, such as the artificial biological heart valve made from bovine pericardium[21]. - The company has a total of 146 R&D personnel, accounting for 27.76% of the total workforce, with an average salary of 128,609.03 RMB per person[64]. - The company reported a total comprehensive income of CNY 60,856,969.18 for the first half of 2024, compared to CNY 49,550,566.81 in the same period of 2023, reflecting an increase of approximately 22.7%[147]. Operational Efficiency and Cost Management - The management highlighted a focus on improving operational efficiency, targeting a 15% reduction in production costs by the end of 2024[1]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[12]. - The company is focusing on increasing operational efficiency and reducing operational costs to enhance business performance[109]. Regulatory and Compliance Risks - The company has identified key risks including regulatory changes and supply chain disruptions, which are discussed in detail in the risk factors section[1]. - Regulatory risks are heightened due to the strict oversight of Class III implantable medical devices, which could affect product approvals and sales if compliance is not maintained[77]. - The company faces risks related to the pace of new product development and market acceptance, which could impact sales performance[74][76]. Environmental and Social Responsibility - The company invested 165,000 RMB in environmental protection during the reporting period[95]. - The company has implemented measures to ensure stable operation of wastewater treatment facilities and conducts regular third-party testing to ensure compliance with environmental standards[96]. - The company does not belong to the key pollutant discharge units as per environmental protection authorities[96]. Shareholder Commitments and Governance - The company has committed to not transferring or managing its shares for 36 months post-listing, ensuring stability in shareholding[100]. - The company confirmed that all related party transactions during the reporting period were disclosed accurately and completely[105]. - The company will ensure that any violations of commitments will result in full compensation for any losses incurred[104].

北京佰仁医疗科技股份有限公司 2024年度"提质增效重回报"行动方案的半年度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，落实"以投资者为本"的发展 理念，推动上市公司持续优化经营、规范治理和积极回报投资者，提高上市公司质量， 助力市场信心提振、资本市场稳定和经济高质量发展，北京佰仁医疗科技股份有限公 司（以下简称"公司"）于 2024 年 4 月 23 日披露了《公司 2024 年度"提质增效重回报" 行动方案》（以下简称"行动方案"），现将公司 2024 年上半年开展和落实行动方案的主 要工作成果报告如下。 一、基于患者的实际临床需求坚持原研创新，加快产品研发和上市 2024 年是公司取得突破性进展的关键时期，基于在心外科长期的积累，公司充分 发挥自有学术影响力，积极倡导瓣膜病全生命周期管理理念，结合新获批限位可扩张 外科瓣产品以及在注册审评产品介入瓣中瓣的临床试验良好表现，为当下中国瓣膜病 患者最大和最迫切的救治需求提供安全有效的治疗方案；近期获批的心脏瓣膜生物补 片也为国内大量主动脉瓣二叶畸形的患者提供了重要的修复手段，进一步丰富了瓣膜 修复产品序列；公司重要在研产品球扩式介入主动脉瓣、介入 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2024-032 北京佰仁医疗科技股份有限公司 关于变更公司注册资本、修订《公司章程》并办理 工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京佰仁医疗科技股份有限公司（以下简称"公司"）于 2024 年 8 月 21 日召 开第三届董事会第五次会议，审议通过了《关于变更公司注册资本、修订<公司 章程>并办理工商变更登记的议案》，现将有关情况说明如下： 一、变更公司注册资本的情况 公司于2024年6月13日召开第三届董事会第三次会议、第三届监事会第三次 会议，审议通过了《关于公司2020年限制性股票激励计划首次授予部分第四个 归属期符合归属条件的议案》《关于公司2020年限制性股票激励计划预留授予 部分第二个归属期符合归属条件的议案》。2024年7月22日，公司2020年限制性 股票激励计划首次授予部分第四个归属期、预留授予部分第二个归属期的股份 登记手续已完成。本次限制性股票归属后，公司的股份总数由13,657.9240万股 增加至13,739. ...